An open label phase I/randomised, double-blind phase II study in metastatic castration resistant Prostate Cancer of AZD5363 in combination with Docetaxel and prednisolone chemotherapy (ProCAID)
Latest Information Update: 02 Nov 2022
At a glance
- Drugs Capivasertib (Primary) ; Docetaxel; Prednisolone
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms ProCAID
Most Recent Events
- 01 Nov 2022 Results of overall survival , published in the European Urology
- 19 Feb 2022 Results presented at the 2022 Genitourinary Cancers Symposium
- 16 Apr 2021 Status changed from active, no longer recruiting to completed.